What changed
Adjusted EPS of $1.31 topped the $1.25 consensus by $0.06, a 4.9% beat, and rose from $1.22 a year ago. Net sales came in at $2.04B, up 1.6% YoY, while net income was $105M. Management raised FY2026 adjusted EPS guidance to $3.83–$3.93 (from $3.73–$3.93) and guided Q4 FY26 adjusted EPS to $0.76–$0.86. The top line benefited from the contractual pass-through of higher raw material costs, with double-digit growth in pharma dispensing products and mid-single-digit growth in fragrance dispensing offsetting softer food and beverage closure demand.
Why it matters
Adjusted EPS of $1.31 topped the $1.25 consensus by $0.06, a 4.9% beat, and rose from $1.22 a year ago. Net sales came in at $2.04B, up 1.6% YoY, while net income was $105M. Management raised FY2026 a